Scarica l'app Stockscreener
1.49
2.76%
0.04
Dopo l'orario di chiusura:
1.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.45
Aprire:
$1.47
Volume 24 ore:
1.33M
Relative Volume:
0.58
Capitalizzazione di mercato:
$190.22M
Reddito:
$79.18M
Utile/perdita netta:
$-136.99M
Rapporto P/E:
-1.4127
EPS:
-1.0547
Flusso di cassa netto:
$-120.11M
1 W Prestazione:
-6.29%
1M Prestazione:
+36.70%
6M Prestazione:
-65.90%
1 anno Prestazione:
-65.02%
Intervallo 1D:
$1.46
$1.565
Intervallo di 1 settimana:
$1.40
$1.87
Portata 52W:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Nome
Adc Therapeutics Sa
Settore
Telefono
41 21 653 02 00
Indirizzo
BIOPOLE, EPALINGES
Compare ADCT vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.49 | 190.22M | 79.18M | -136.99M | -120.11M | -1.0547 |
TAK
Takeda Pharmaceutical Co Adr
|
19.45 | 62.13B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.11 | 47.95B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.94 | 43.71B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.42 | 32.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.51 | 23.23B | 3.17B | 1.29B | 1.01B | 27.09 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-08 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-06-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Iniziato | Guggenheim | Buy |
| 2023-08-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Iniziato | CapitalOne | Overweight |
| 2022-11-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-08-17 | Ripresa | Jefferies | Buy |
| 2021-08-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-09 | Iniziato | BofA/Merrill | Buy |
| 2020-06-09 | Iniziato | Cowen | Outperform |
Mostra tutto
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Hold" from Brokerages - marketbeat.com
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow - Seeking Alpha
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com Nigeria
ADCT: ZYNLONTA shows high response rates and regulatory momentum in DLBCL and lymphoma studies - TradingView
ADCT: Promising LOTIS-7 results and robust cash position support expansion in lymphoma markets - TradingView
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com India
ADC Therapeutics at Cantor conference: zynlonta growth plan faces FDA test - Investing.com UK
ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.9%Time to Sell? - marketbeat.com
ADC Therapeutics SA (ADCT) Stock Price & News - Syfe
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - morningstar.com
ADC Therapeutics (ADCT) Navigates FDA Setback While Cutting Its Losses - Yahoo Finance
ADC Therapeutics SA (ADCT) Stock News Today - TradingKey
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript - AOL.com
ADC Therapeutics SA (NYSE:ADCT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Following a 56% Decline Over Last Year, Recent Gains May Please ADC Therapeutics SA (NYSE:ADCT) Institutional Owners - 富途牛牛
Guggenheim cuts ADC Therapeutics stock price target on FDA concerns By Investing.com - Investing.com South Africa
Guggenheim cuts ADC Therapeutics stock price target on FDA concerns By Investing.com - Investing.com UK
Antibody-Drug Conjugates (ADC) Market Set to Witness Significant - The National Law Review
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Zynlonta Outlook - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Rating Increased to Hold at Wall Street Zen - MarketBeat
Nantahala group discloses 9.69% ADC Therapeutics (ADCT) ownership in 13G filing - Stock Titan
ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says - marketscreener.com
ADC Therapeutics S.A. Q2 2026 Earnings Call Summary - Yahoo Finance
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo! Finance Canada
ADC Therapeutics Q2 Earnings Call Highlights - MarketBeat
ADC Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
ADC Therapeutics (NYSE:ADCT) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ADC Therapeutics SA: Shareholders Board Members Managers and Company Profile | CH0499880968 - marketscreener.com
ADC Therapeutics Q2 Results: Net Loss Falls 71% to $16.6 Million - scanx.trade
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Nigeria
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Australia
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com South Africa
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com India
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com Canada
Form 8K ADC Therapeutics SA For: 13 August By Investing.com - Investing.com UK
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings call transcript: ADC Therapeutics beats Q2 2026 estimates but shares fall - Investing.com
ADC Therapeutics Q2 2026 Earnings Call Transcript - Benzinga
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings - Moomoo
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q2 2026 Earnings | ADCT Stock News - Quiver Quantitative
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss - TradingKey
ADC Therapeutics SA (ADCT) Latest Stock News & Headlines - Yahoo Finance
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - Yahoo Finance
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - Finansavisen
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo Finance
Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - GuruFocus
Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adc Therapeutics Sa Azioni (ADCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 10% Owner |
Apr 02 '26 |
Sale |
3.28 |
2,529,491 |
8,294,201 |
10,265,297 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
169,265 |
643,038 |
15,301,237 |
| Redmile Group, LLC | 10% Owner |
Apr 01 '26 |
Sale |
3.80 |
162,517 |
617,402 |
12,794,788 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
196,229 |
736,251 |
15,470,502 |
| Redmile Group, LLC | 10% Owner |
Mar 31 '26 |
Sale |
3.75 |
188,407 |
706,903 |
12,957,305 |
0.93%
2.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):